{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:03:09Z","timestamp":1759334589998,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jfo.2020.10.007","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T08:59:48Z","timestamp":1617613188000},"page":"e429-e430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ocular toxicity of bortezomib therapy"],"prefix":"10.1016","volume":"44","author":[{"given":"B.","family":"Arias-Peso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bakkali el Bakkali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tello Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.A.","family":"Rodriguez-Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2020.10.007_bib0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","article-title":"Bortezomib for the treatment of hematologic malignancies: 15 years later","volume":"19","author":"Robak","year":"2019","journal-title":"Drugs RD"},{"key":"10.1016\/j.jfo.2020.10.007_bib0050","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jfo.2015.05.004","article-title":"Effets ind\u00e9sirables oculaires des traitements syst\u00e9miques: une mise \u00e0 jour","volume":"38","author":"Rousseau","year":"2015","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2020.10.007_bib0055","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaophthalmol.2015.3963","article-title":"Association between bortezomib therapy and eyelid chalazia","volume":"134","author":"Fraunfelder","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2020.10.007_bib0060","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/j.jfo.2017.09.029","article-title":"Chalazia associated with bortezomib therapy","volume":"41","author":"Laaribi","year":"2018","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2020.10.007_bib0065","first-page":"5","article-title":"Bortezomib-induced blepharitis: a case report","volume":"5","author":"Khalil","year":"2020","journal-title":"Int J Cancer Res Ther"},{"key":"10.1016\/j.jfo.2020.10.007_bib0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0181-5512(04)96103-7","article-title":"Palpebral edema secondary to treatment by a specific inhibitor of tyrosine kinase: Glivec\u00ae. A case report","volume":"27","author":"Maalouf","year":"2004","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2020.10.007_bib0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12886-019-1118-x","article-title":"Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series","volume":"19","author":"Sklar","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2020.10.007_bib0080","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.clml.2016.04.013","article-title":"Treatment With doxycycline for severe bortezomib-associated blepharitis","volume":"16","author":"Veys","year":"2016","journal-title":"Clin Lymphoma, Myeloma Leuk"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551221001613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551221001613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:17:10Z","timestamp":1759259830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551221001613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0181551221001613"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2020.10.007","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular toxicity of bortezomib therapy","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2020.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}